Meanwhile, the role of ICI therapy in EGFRm NSCLC is complex, with many studies describing additive toxicities without clinical benefit in combination ICI + EGFR TKI treatment models as described above. This evidence concerns the gene EGFR and non-small cell lung carcinoma.